MedPath

Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)

Completed
Conditions
Malignant Pleural Mesotheliomas
Registration Number
NCT02603315
Lead Sponsor
Ain Shams University
Brief Summary

The purpose of this study is to To assess the correlation between the predictive factor of vascularity (CD74) in malignant pleural mesothelioma and treatment results (response rate, and overall survival) .

Detailed Description

This is a randomized controlled retrospective study through Examination of paraffin blocks of the patient selected to be included in the study for assessment of the selected vascularity marker of malignant pleural mesothelioma of both types . The CD74 (LN2) antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed paraffin-embedded tissue sections using Immunohistochemistry test methods.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Histopathological confirmation of malignant pleural mesothelioma .

  • Full clinical data.

  • Availability for follow up: Personal communication will be attempted in order to collect missing information.

    3-The files of all patients will be reviewed to analyze the following :

  • Operative data if done .

  • Pathological review and immunohistochemistry.

  • Laboratory investigations: (routine investigations: complete blood picture,liver and renal function test)

  • Radiological investigations:( CXR and CT-chest, Abdominal and pelvic U\S and MRI ).

  • Treatment protocols applied: Radiotherapy and Chemotherapy.

  • Response and survival after treatment .

Exclusion Criteria
  • cases not receive chemotherapy ,on available of evaluation after treatment

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
to correlate the results of the vascularity marker of pleural mesothelioma CD74 of patients attended to Ain Shams University hospitals with the result response of treatment by chemotherapy ,overall survival and progreeion free survival3-4 months

The cases diagnosed and receive at the least 2-3 cycles of chemotherapy and evaluated after treatment

Secondary Outcome Measures
NameTimeMethod
assessment of vascular enothelial growth factor (VEGF) in patient with malignant pleural mesothelioma who attended to Ain Shams University and made comparison with the result of CD 743-4 months

The cases diagnosed and receive at the least 2-3 cycles of chemotherapy and evaluated after treatment

Trial Locations

Locations (1)

Ain Shams University Hospital

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath